{"id":"NCT00269087","sponsor":"GlaxoSmithKline","briefTitle":"GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)","officialTitle":"Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)\" A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease -","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01-28","primaryCompletion":"2006-10-01","completion":"2006-10-25","firstPosted":"2005-12-23","resultsPosted":"2019-02-01","lastUpdate":"2019-02-01"},"enrollment":122,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"fluticasone propionate/salmeterol combination DISKUS","otherNames":[]}],"arms":[],"summary":"This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects will be given breathing tests, and will record their breathing symptoms daily on diary cards.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)","timeFrame":"Up to Week 56","effectByArm":[{"arm":"GW815SF 50/500 µg","deltaMin":120,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":122},"commonTop":["Nasopharyngitis","Dysphonia","Oral candidiasis","Chronic obstructive airways disease exacerbated","Upper respiratory tract inflammation"]}}